Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354068 · ClinicalTrials.gov registry record · Phase 1
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00354068 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 65 participants.
The verdict
NCT00354068, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with temozolomide in treating patients with malignant glioma.
Interventions
- DRUG temozolomide
- DRUG imatinib mesylate
- OTHER pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00354068
The ClinicalTrials.gov registry entry for NCT00354068 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which temozolomide is the first listed.
NCT00354068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00354068 about?
NCT00354068 is a clinical study titled "Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma". RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving im...
What is the current status of trial NCT00354068?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2004-07. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00354068?
The interventions under investigation include: temozolomide (DRUG), imatinib mesylate (DRUG), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT00354068?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.